EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)

Haploidentical haematopoietic stem cell transplantation for thalassaemia major: A phase IV , open‐label, single‐centre trial

Xiaoxuan Lai iD, Rongrong Liu iD, Hongwen Xiao iD, Lianjin Liu, Zhenbin Wei iD, Lingling Shi, Meiqing Wu, Zhongming Zhang, Yongrong Lai iD

British Journal of Haematology · 2026-11 · 209 (5) · 2213-2222

DOI: 10.1111/bjh.70819 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift British Journal of Haematology, online erschienen am 01.09.2026. Verfasst von Xiaoxuan Lai und 8 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Transplantation, Haploidentical, beta-Thalassemia. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report the results of an open‐label, single‐centre phase 4 clinical trial evaluating haploidentical haematopoietic stem cell transplantation (Haplo‐HSCT) in patients with transfusion‐dependent thalassaemia (TDT). A total of 134 patients with TDT were enrolled; the median age was 8.7 years (interquartile range [IQR], 6.0–11.7 years; range, 3–20 years). All patients received a uniform conditioning regimen consisting of busulfan, cyclophosphamide, fludarabine and anti‐thymocyte globulin (ATG). Graft‐versus‐host disease (GVHD) prophylaxis included methotrexate (MTX), mycophenolate mofetil (MMF) and tacrolimus. The primary end‐point was 2‐year overall survival (OS). Median follow‐up is 23.4 months (IQR: 11.5–38.7; range: 6.1–81.5). The 2‐year OS, event‐free survival (EFS) and graft‐versus‐host disease‐free, relapse‐free survival (GRFS) rates were 93.4%, 92.6% and 77.5% respectively. The cumulative incidence rates of aGVHD, grade 2–4 aGVHD and grade 3–4 aGVHD were 47.8%, 30.9% and 12.5% respectively. Donor‐specific antibodies (DSAs) and male‐recipient/female‐donor pairing were associated with inferior OS ( p = 0.021; p = 0.010) and EFS ( p = 0.040; p = 0.020). Hepatomegaly (≥5 cm) was associated with inferior OS ( p = 0.037). Collectively, these findings support Haplo‐HSCT as a key curative option for TDT patients in the absence of fully matched donors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationTransplantation, Haploidenticalbeta-ThalassemiaHumansFemaleMaleChildChild, PreschoolTransplantation ConditioningAdolescentGraft vs Host DiseaseYoung AdultDisease-Free SurvivalImmunosuppressive AgentsTreatment Outcome

Stichwörter der Autor:innen

Haplo‐HSCTTDT

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
  • NHC Key Laboratory of Thalassemia Medicine, Nanning, Guangxi, China.
  • Guangxi Key Laboratory of Thalassemia Research, Nanning, Guangxi, China.

ORCID-Profile: Xiaoxuan Lai, Rongrong Liu, Hongwen Xiao, Zhenbin Wei, Yongrong Lai

Zitieren

APA

Lai, X., Liu, R., Xiao, H., Liu, L., Wei, Z., Shi, L., Wu, M., Zhang, Z., & Lai, Y. (2026). Haploidentical haematopoietic stem cell transplantation for thalassaemia major: A phase IV , open‐label, single‐centre trial. British Journal of Haematology, 209(5), 2213-2222. https://doi.org/10.1111/bjh.70819

Vancouver

Lai X, Liu R, Xiao H, Liu L, Wei Z, Shi L, et al. Haploidentical haematopoietic stem cell transplantation for thalassaemia major: A phase IV , open‐label, single‐centre trial. British Journal of Haematology. 2026;209(5):2213-2222. doi:10.1111/bjh.70819

BibTeX
@article{Lai2026,
  author = {Lai, Xiaoxuan and Liu, Rongrong and Xiao, Hongwen and Liu, Lianjin and Wei, Zhenbin and Shi, Lingling and Wu, Meiqing and Zhang, Zhongming and Lai, Yongrong},
  title = {Haploidentical haematopoietic stem cell transplantation for thalassaemia major: A phase IV , open‐label, single‐centre trial},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {209},
  number = {5},
  pages = {2213--2222},
  doi = {10.1111/bjh.70819}
}
Kostenlos starten →